Skip to main content

RAD April 2023 Conference Abstracts and Posters

All accepted abstracts have been published in The British Journal of Dermatology, Volume 188, Issue Supplement 3, June 2023. You may access the publication at:

#421 - The role of itch resolution and skin clearance in patient-reported atopic dermatitis severity and quality of life: Insights from a real-world analysis of the TARGET-DERM AD registry

Jonathan I. Silverberg, Keith D. Knapp, Breda Munoz, Julie M. Crawford, Brian Calimlim, Ayman Grada, Amy S. Paller on behalf of the TARGET-DERM Investigators

#422 - Healthcare disparities in atopic dermatitis: insights from TARGET-DERM registry

Lara Wine Lee, Keith Knapp, Breda Munoz, Anthony Perez, Chibuzo Obi, Brian Calimlim, Ayman Grada, Jonathan I. Silverberg

#423 - Long-term efficacy of abrocitinib up to 96 weeks in adults with moderate-to-severe atopic dermatitis stratified by age: a post hoc analysis of the JADE EXTEND phase 3 trial

Andrew F. Alexis, Mette Deleuran, Jonathan I. Silverberg, Melinda J. Gooderham, Saleem A. Farooqui, Gary Chan, Herwig Koppensteiner, Pinaki Biswas, Melissa Watkins

#424 - Effect of abrocitinib versus dupilumab on skin pain: an analysis of the phase 3 JADE COMPARE and JADE DARE trials

Jacob P. Thyssen, Anthony Bewley, Sonja Ständer, Carla Castro, Laurent Misery, Laura von Kobyletzki, Jonathan I. Silverberg, Brian S. Kim, Pinaki Biswas, Gary Chan, Daniela E. Myers, Melissa Watkins, Justine Alderfer, Erman Güler

#425 - Effect of upadacitinib on SCORAD intensity items: analysis from the Measure Up 1 and Measure Up 2 studies

Michael Cameron, Nina Magnolo, Vimal H. Prajapati, Adel Haque, Wan-Ju Lee, Katherine Altman, Andrew M. Platt, Michael C. Lane, Brian M. Calimlim, Alain Taieb

#426 - Efficacy and safety of abrocitinib in adolescents with moderate-to-severe atopic dermatitis from the JADE clinical trial program

Lawrence F. Eichenfield, Carsten Flohr, Christine Bangert, Alan D. Irvine, Stephan Weidinger, John Nesnas, Herwig Koppensteiner, Fan Zhang, Ricardo Rojo, Gary Chan

#427 - Long-term 4-year safety of upadacitinib in moderate-to-severe atopic dermatitis: Results of an integrated analysis of phase 3 studies

Jonathan I. Silverberg, Christopher G. Bunick, Peter Lio, Emma Guttman-Yassky, Mark Boguniewicz, Andrew Blauvelt, Thomas Bieber, Jacob P. Thyssen, Smitha Suravaram, Nasser S. Khan, Deanne M. Dilley, Henrique D. Teixeira, Namita V. Vigna, Amy Gamelli, Ayman Grada, Alan D. Irvine

#428 - Evaluating chronic pruritus prevalence, characteristics, and effects on atopic dermatitis patients from a referral university hospital in São Paulo, Brazil: a cross-sectional study

Georgia Biazus Soares, Raquel Leão Orfali, Beatriz Lacerda Averbach, Gil, Yosipovitch, Valeria, Aoki

#429 - Differentiation of IL-22 levels in inflammatory diseases using a high sensitivity ELISA

Alok Pandey, Alka Bansal, Elfie DeJesus, Greggory Kisiel, William A. Clark, Michael Skawinski, Thomas B. Lavoie

#430 - Comparison of effectiveness of topical treatments for atopic dermatitis

Sabiha Uddin, Britton Upchurch, Rithi J. Chandy, Steven R. Feldman

Page 5 of 6
Results 41 - 50 of 60